Did you know?

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) shares gapped up before the market opened on Wednesday .The stock had previously closed at $11.69, but opened at $12.14. Neumora ...Sep 12, 2023 · A Quick Take On Neumora Therapeutics. Neumora Therapeutics, Inc. ( NASDAQ: NMRA) has filed proposed terms to raise $250 million from the sale of its common stock in an IPO, according to an amended ... Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor, a clinically validated target for the treatment of schizophrenia WATERTOWN, Mass., Nov. 27, 2023 (GLOBE ... Sep 15, 2023 · The Watertown, MA-based Neumora Therapeutics ( NASDAQ: NMRA ), a Phase 3 biotech developing therapies for brain diseases has priced its initial public offering of 14.71 million shares of its ... Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) shares gapped up before the market opened on Wednesday .The stock had previously closed at $11.69, but opened at $12.14. Neumora ...Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study. Nov 28. Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million. Sep 16. Earnings and Revenue Growth Forecasts. NasdaqGS:NMRA - Analysts future estimates and past financials data (USD Millions) DateNeumora Therapeutics, Inc. (NASDAQ:NMRA) as filed to raise $100 million in an IPO of its common stock, according to an SEC S-1 registration statement.Neumora Therapeutics (NASDAQ:NMRA) stock dipped 4% in late afternoon trading Friday following a $250M IPO. Shares of the psychiatric drug developer opened at $16.50 after being priced at $17 per ...WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ...The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by UBS on Tuesday, September 26, 2023. The analyst firm set a price target for 25.00 expecting CBAY to rise to within ...For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.View real-time NMRA stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA Get Free Report) traded up 4.6% on Friday . The stock traded as high as $11.21 and last traded at $11.09. 32,521 shares were traded during... Share to Feed. Insider Buying: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Major Shareholder Purchases 30,192 Shares of Stock Ticker Report • …Created with Sketch. when trading, helping you to optimize your price and have a successful order execution. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4 ...4 hari yang lalu ... Moleculin Biotech (NASDAQ:MBRX) stock is jumping more than 15% without any clear news today. Neumora Therapeutics (NASDAQ:NMRA) shares are up ...Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares fell 8% to $11.02. Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) fell 7.4% to $9.97. BeiGene, Ltd. (NASDAQ:BGNE) fell 7.2% to $193.86. B of A ...SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 0.58. At the close of trading, the stock’s price was $20.71, to imply a decrease of -2.08% or -$0.44 in intraday trading. The SWTX share’s 52-week ...

Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug ...--Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Robert Lenz, M.D., Ph.D., as executive vice ...WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided ... (NMRA-140) is a highly selective, novel, …

NMRA | Complete Neumora Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Neumora Therapeutics, Inc. (NASDAQ: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the pricing of its initial public offering of ...View NMRA historial stock data and compare to other stocks and exchanges. ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Stock analysis for Neumora Therapeutics Inc . Possible cause: The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by Cant.